Principal Financial Group Inc Acelrx Pharmaceuticals Inc Transaction History

Principal Financial Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 09, 2022	SELL	$0.49 - $1.02 $11,578 - $24,102	-23,630 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$0.93 - $1.51 $3,561 - $5,783	-3,830 Reduced 13.95%	23,630 $24,000
Q2 2021 Aug 10, 2021	BUY	$1.03 - $1.7 $17,857 - $29,472	17,337 Added 171.26%	27,460 $37,000
Q2 2020 Aug 05, 2020	SELL	$1.03 - $1.69 $1,516 - $2,487	-1,472 Reduced 12.7%	10,123 $12,000
Q4 2019 Feb 05, 2020	SELL	$1.66 - $2.4 $1,434 - $2,073	-864 Reduced 6.93%	11,595 $24,000
Q3 2019 Nov 13, 2019	BUY	$2.1 - $2.87 $1,478 - $2,020	704 Added 5.99%	12,459 $27,000
Q2 2019 Aug 12, 2019	BUY	$2.1 - $3.93 $24,685 - $46,197	11,755 New	11,755 $30,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.